SSR 69071

Drug Profile

SSR 69071

Latest Information Update: 23 Jun 2003

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Sanofi-Synthelabo
  • Class
  • Mechanism of Action Leucocyte elastase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • Discontinued Chronic obstructive pulmonary disease

Most Recent Events

  • 23 Jun 2003 Discontinued - Preclinical for Chronic obstructive pulmonary disease in France (unspecified route)
  • 17 Sep 2002 Preclinical data from the XVIIth Int Med Chem Symp have been added to the pharmacodynamics section
  • 12 Sep 2000 Preclinical development for Chronic obstructive pulmonary disease in France (Unknown route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top